Navigating Geisinger Health Plan Skyrizi Prior Authorization
Efficiently managing Geisinger Health Plan Skyrizi prior authorization is critical for patient access and revenue cycle integrity. Klivira provides the automation necessary to navigate these complex requirements.
For revenue cycle directors and prior authorization coordinators, understanding the specific requirements for high-cost biologics like Skyrizi (risankizumab) under Geisinger Health Plan is paramount. The nuances of formulary placement, step-therapy protocols, and specialty pharmacy mandates can significantly impact approval times and resource allocation. Klivira offers a structured approach to automate and optimize these workflows.
Geisinger Health Plan Formulary Placement for Skyrizi
Skyrizi, an IL-23 inhibitor indicated for conditions such as plaque psoriasis, psoriatic arthritis, and Crohn's disease, is typically positioned on a specialty tier within Geisinger Health Plan's formulary. This placement necessitates a prior authorization (PA) submission and often involves specific coverage criteria to ensure medical necessity and appropriate utilization according to Geisinger's benefit design.
Prior Authorization Requirements and Clinical Criteria
Geisinger Health Plan's prior authorization process for Skyrizi will evaluate adherence to established clinical guidelines. Providers must document the diagnosis, severity of the condition, and often, prior treatment failures or contraindications to alternative therapies. For example, in psoriasis or psoriatic arthritis, documentation of prior systemic therapy failure or specific disease activity scores may be required.
Common Step-Therapy and Quantity Limit Hurdles
- **Step-Therapy Protocols**: Geisinger Health Plan typically requires documentation of an adequate trial and failure of conventional systemic therapies (e.g., methotrexate) or other biologics before approving Skyrizi.
- **Quantity Limits**: Adherence to FDA-approved dosing schedules is strictly enforced. Geisinger Health Plan will apply quantity limits based on the prescribed indication (e.g., plaque psoriasis, psoriatic arthritis, Crohn's disease) and frequency.
- **Diagnosis-Specific Criteria**: PA approval is contingent on the specific indication matching Geisinger's medical policies for risankizumab, requiring detailed clinical notes and diagnostic reports.
- **Provider Specialty**: Submissions often require a prescribing provider within a relevant specialty (e.g., dermatology, gastroenterology, rheumatology) to ensure appropriate clinical oversight.
PBM Partnership and Specialty Pharmacy Routing
Like many regional payers, Geisinger Health Plan partners with a Pharmacy Benefit Manager (PBM) to manage its prescription drug benefits. Skyrizi, as a high-cost specialty biologic, will almost certainly be routed through a designated specialty pharmacy within Geisinger's network or its PBM's network. This requires precise e-prescribing and fulfillment coordination to prevent delays.
Automating Geisinger Health Plan Skyrizi PA Submissions
Klivira integrates with EMRs to automate the collection of clinical data and streamline the submission of X12 278 transactions or ePA forms for Geisinger Health Plan Skyrizi prior authorization. Our platform helps identify missing information proactively, reducing manual effort and resubmission rates. This accelerates approval cycles and improves patient access to essential IL-23 inhibitor therapy.
Frequently asked questions
What is the typical formulary tier for Skyrizi under Geisinger Health Plan?
Skyrizi (risankizumab) is generally placed on a specialty drug tier within Geisinger Health Plan's formulary. This classification means it requires prior authorization and often has specific coverage criteria and benefit limitations.
Does Geisinger Health Plan require step-therapy for Skyrizi?
Yes, Geisinger Health Plan typically mandates step-therapy protocols for Skyrizi. This often involves documenting the failure of, or contraindication to, less costly alternative treatments before Skyrizi can be approved for conditions like plaque psoriasis, psoriatic arthritis, or Crohn's disease.
How does Klivira help with Geisinger Health Plan Skyrizi prior authorization?
Klivira automates the prior authorization process by integrating with your EMR to extract necessary clinical data, populate PA forms, and submit them via X12 278 or ePA. This reduces manual tasks, minimizes errors, and proactively identifies missing information, accelerating approvals for Geisinger Health Plan members.
Will Skyrizi be dispensed through a specialty pharmacy for Geisinger Health Plan members?
Yes, as a specialty biologic, Skyrizi for Geisinger Health Plan members will almost certainly be dispensed through a designated specialty pharmacy. This is a common practice for high-cost, high-touch medications requiring specialized handling and patient support.
What documentation is crucial for Skyrizi PA approval with Geisinger Health Plan?
Key documentation includes detailed clinical notes supporting the diagnosis (e.g., plaque psoriasis, psoriatic arthritis, Crohn's disease), severity of the condition, results of diagnostic tests, and a comprehensive history of prior treatment failures or contraindications to other therapies as per Geisinger's medical policies.
Related coverage
Ready to automate prior auth for this plan?
See how Klivira automates prior authorizations for your team.
Request a demo